Investigation Alert: uniQure Faces Scrutiny Following Recent Stock Plunge

In a startling turn of events, shares of uniQure N.V. (NASDAQ: QURE) plummeted 39% on September 29, 2026, following the release of disappointing results from its AMT-130 clinical trial for Huntington's disease. Investors are now facing a potential crisis, and SueWallSt has stepped in to notify affected stakeholders of a pending investigation related to this matter.

Stock Market Impact

The decline in share price came after the company revealed that the benefits of its AMT-130 treatment were significantly less than what had been reported previously. The drug, designed to slow the progression of Huntington's disease, showed only a 44% reduction in disease advancement over a 48-month period according to the Uniform Huntington's Disease Rating Scale. This result starkly contrasts with the 75% reduction claimed at the three-year mark, raising concerns among investors about the reliability of the data.

The fallout was immediate. After a promising spike in June, when uniQure announced its intention to seek FDA approval to bring the drug to market, the subsequent four-year data released has raised red flags—leading to questions about the company's transparency and the accuracy of its earlier statements. In fact, the timeline of events indicates that uniQure submitted a Biologics License Application to the FDA based on the earlier, more favorable data just weeks before the disappointing results became public.

Investor Rights

In the wake of these developments, investors who have experienced losses on their QURE holdings are urged to act quickly. Legal action is being advised, and those investors are encouraged to submit their loss information to determine their eligibility for participation in the investigation. Joseph E. Levi, Esq., representing SueWallSt, is available for consultation via email or phone, with no upfront costs for evaluation.

In light of this situation, it’s essential for investors to gather relevant brokerage records that detail their purchase dates, share quantities, prices paid, and any subsequent sale details. Misleading statements concerning the AMT-130 trial outcomes are at the center of the investigation, and if you have sold your shares at a loss, you still retain the right to pursue legal action based on your purchase history.

Frequently Asked Questions

1. What statements are under investigation?
The focus is on whether uniQure misrepresented its AMT-130 program's clinical results and the durability of such results prior to the most recent data release.

2. What should impacted investors do?
Investors are advised to compile their documentation and reach out for a free assessment of their potential recovery.

3. What if I live outside the U.S.?
U.S. securities investigations can cover purchases made on American exchanges, regardless of the investor’s location.

SSueWallSt, powered by Levi & Korsinsky LLP, has a long-standing track record of advocating for shareholders. The firm has successfully represented investors in high-stakes securities litigation, securing substantial settlements. The current investigation into uniQure emphasizes the importance of investor vigilance, especially with the implications that misleading data can have on stock value and investor trust.

As the situation unfolds, affected shareholders are urged to stay informed and proactive, ensuring their rights are considered amidst the repercussions of uniQure's recent trial results.

For any inquiries or to begin the evaluation process, investors can contact Joseph E. Levi's office directly for assistance.